Showing results (101-110 of 444) with videos related to
Sort By:
Pageof 45
Journal of Neuro-Oncology|June 19, 2025
Long-term clinical outcomes of bevacizumab for treatment of stereotactic radiosurgery-induced radiation necrosis in patients with brain metastasesKylie Jung, Sudhir Das Sivadas, Xavier Fitzgerald, et al.Journal of Hepatology|February 25, 2021
Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitisCathrin L C Gudd, Lewis Au, Evangelos Triantafyllou, et al.Nature Communications|August 1, 2020
Escape from nonsense-mediated decay associates with anti-tumor immunogenicityKevin Litchfield, James L Reading, Emilia L Lim, et al.European Journal of Cancer (Oxford, England : 1990)|October 23, 2018
Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infectionMartin Tio, Rajat Rai, Ogochukwu M Ezeoke, et al.BMC Public Health|June 15, 2022
Self-rated health and quality of life among Syrian refugees in Ireland - data from a cross-sectional studyClaire Collins, Ivana Pericin, James Larkin, et al.BJGP Open|December 20, 2018
Future career intentions of recent GP graduates in Ireland: a trend analysis studyIvana Pericin, Gerard Mansfield, James Larkin, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2014
Immuno-oncology combinations: a review of clinical experience and future prospectsScott J Antonia, James Larkin, Paolo A AsciertoLancet (London, England)|September 12, 2021
Immune checkpoint inhibitors in melanomaMatteo S Carlino, James Larkin, Georgina V LongJournal for Immunotherapy of Cancer|July 8, 2021
Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximabJames L Alexander, Hajir Ibraheim, Bhavisha Sheth, et al.Cell Reports. Medicine|February 28, 2024
Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trialJames Larkin, Richard Marais, Nuria Porta, et al.Pageof 45